Tilmanocept

Overview

Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).

Background

Indication

No indication information available.

Associated Conditions

Breast Cancer
Melanoma
Oral Cancer

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept	2021/07/01	NCT04947137	Phase 2	Completed	Navidea Biopharmaceuticals
Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma	2020/12/10	NCT04663126	Early Phase 1	Terminated	John O. Prior
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer	2020/08/12	NCT04511026	Phase 2	Terminated	Stanford University
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer	2020/07/27	NCT04487912	Phase 4	Withdrawn	University Hospital, Ghent
Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer	2020/02/07	NCT04261179	Phase 4	UNKNOWN	Anna Cruceta
Mapping Draining Lymph Nodes in CNS Malignancies	2019/09/20	NCT04096716	Phase 1	Terminated	Washington University School of Medicine
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA	2019/09/04	NCT04078191	Phase 2	Terminated	Navidea Biopharmaceuticals
Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	2019/05/06	NCT03938636	Phase 2	Completed	Navidea Biopharmaceuticals
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer	2018/01/19	NCT03405142	Phase 2	Completed	Eben Rosenthal
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	2017/08/07	NCT03241446	Phase 1	Withdrawn	Navidea Biopharmaceuticals

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Lymphoseek	Navidea Biopharmaceuticals Europe Ltd.,Kilminion South,Ballinroad,Dungarvan,Co. Waterford, X35 WP70,Ireland	Withdrawn	11/19/2014

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access